Growing cooperation among pharmaceutical and biotech companies could help speed market approval for drugs as partnerships combine resources, an ISMPP report states, a “good outcome for patients.”
However, the partnerships present their own set of obstacles.
“Since the processes, structures, and even the cultures of the two entities may differ in significant ways, many decisions need to be made along the drug development continuum about whose processes to follow or if a new process will be established specifically for the partnership,” the report by Merk and Co.’s Carolyn Hustad states.
Partnered entities could also run into some hang-ups with joint publications due to a potentially complex decision-making construct.
“Decisions have to be made about which roles from each company will be on the joint publication team, as well as who needs to review joint publications and what the review timelines will be,” Hustad writes.
Read the full report here.